The global healthcare industry is experiencing a paradigm shift in rare cancer treatment, with mantle cell lymphoma (MCL) representing a critical area of therapeutic advancement. This uncommon yet challenging hematologic malignancy affects approximately 3,000-4,000 new patients annually in the United States, creating substantial market potential for innovative...